European shares ended Wednesday's choppy session higher, as a rise in healthcare companies GSK and Novo Nordisk following ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its mid-December bear gap, after which it hit a Jan. 17, 52-week low of $78.17 amid ...

Novo Nordisk defended its obesity drug CagriSema despite disappointing trial data. The company remains optimistic about its efficacy compared to Wegovy. Upcoming trials aim to harness its weight-loss ...

The Danish pharmaceutical company expects demand for obesity and diabetes drugs to rise, but forecasts sales growth to slow down this year. Read more.

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Danish weight-loss drug maker Novo Nordisk (NVO) is jumping 5% after the company reported higher-than-expected net income for ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...